Techsomed, a Rehovot, Israel-based developer of an image analysis system for predicting post-treatment ablation morphology in real time,secured $2.6M in funding.
The round was led by Johnson & Johnson Innovation – JJDC, Inc., with participation from existing and new investors Screen Holdings, AMIT-Technion (the Alfred Mann Institute), NextLeap Ventures, and Axil Capital.
The company intends to use the funds for further development towards obtaining FDA, PMDA, and CE regulatory approval.
Led by Says founder and CEO Yossi Abu, Techsomed is a biotech company which develops ultrasound-based real-time monitoring systems for thermal ablation procedures. Using advanced proprietary AI and image analysis, its BioTrace™ system integrates with standard ultrasound devices to track the target tissue’s unique biological signature as it responds to heat during thermal ablation. This signature is used to visually simulate the post 24-hour thermal effect in real-time, thus enhancing the surgeon’s level of control and accuracy during the procedure.